Compare ENGN & ABLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ENGN | ABLV |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.2M | 121.5M |
| IPO Year | 2023 | 2022 |
| Metric | ENGN | ABLV |
|---|---|---|
| Price | $1.95 | $2.30 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $4.29 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 101.9K |
| Earning Date | 12-21-2026 | 12-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $16.70 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.40 | $0.54 |
| 52 Week High | $12.25 | $2.96 |
| Indicator | ENGN | ABLV |
|---|---|---|
| Relative Strength Index (RSI) | 55.31 | 51.62 |
| Support Level | $1.61 | $0.75 |
| Resistance Level | $8.93 | $2.91 |
| Average True Range (ATR) | 0.18 | 0.36 |
| MACD | 0.07 | -0.06 |
| Stochastic Oscillator | 47.17 | 40.44 |
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.